The devil we know: Is the use of injectable agents for the treatment of MDR-TB justified?

International Journal of Tuberculosis and Lung Disease

Volumn 21, Issue 11, 2017, Pages

  Reuter, A ^a   Tisile, P ^b   Von Delft, D ^b   Cox, H ^c   Cox, V ^c   Ditiu, L ^d   Garcia Prats, A ^e   Koenig, S ^f   Lessem, E ^g   Nathavitharana, R ^h   Seddon, J A ⁱ   Stillo, J ^j   Von Delft, A ^b,c   Furin, Jennifer ^f  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b TB Proof   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Stop TB Partnership   (Switzerland)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Treatment Action Group   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

Drug resistant TB; Hearing loss; Injectable agents; MDR TB; Ototoxicity

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; DELAMANID; INJECTABLE AGENT; LINEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ELECTROCARDIOGRAPHY MONITORING; ELECTROLYTE DISTURBANCE; HEARING IMPAIRMENT; HUMAN; HUMAN RIGHTS; INJECTION SITE INJURY; INJECTION SITE PAIN; INJECTION SITE REACTION; MEDICAL ETHICS; MULTIDRUG RESISTANT TUBERCULOSIS; NEPHROTOXICITY; OTOTOXICITY; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QTC INTERVAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT INDICATION; VESTIBULAR DISORDER; HEALTH CARE DELIVERY; INJECTION;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; HEALTH SERVICES ACCESSIBILITY; HUMAN RIGHTS; HUMANS; INJECTIONS; NITROIMIDAZOLES; OXAZOLES; PATIENT-CENTERED CARE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85031500611     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.17.0468     Document Type: Review

References (134)

1. World Health Organization. WHO treatment guidelines for drug resistant tuberculosis: 2016 update. WHO/HTM/TB/ 2016.04. Geneva, Switzerland: WHO, 2016.
2. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527–532.
3. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575–1580.
4. Garcia-Prats A J, Donald P R, Hesseling A C, et al. Second-line anti-tuberculosis drugs in children: a commissioned review for the World Health Organization 19th expert committee on the selection and use of essential medicines. Geneva, Switzerland: World Health Organization, 2013. http://www.who.int/entity/selection_medicines/committees/expert/19/applications/TB_624_C_R.pdf Accessed July 2017.
5. Shringarpure K S, Isaakidis P, Sagili KD, Baxi R K, Das M, Daftary A. ‘When treatment is more challenging than the disease’: a qualitative study of MDR-TB patient retention. PLOS ONE 2016; 11: e0150849.
6. Keal J L, Khachi H, Hanzaree E, White V L C. Treatment of multidrug resistant tuberculosis: where are the guidelines for monitoring? Thorax 2011; 66: A91. [Abstract P56]
7. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314–1320.
8. Torun T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373–1377.
9. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of multidrug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, Switzerland: WHO, 2014.
10. Furin J, Brigden G, Lessem E, Rich M, Vaughan L, Lynch S. Global progress and challenges in the implementation of new medications for the treatment of multidrug-resistant tuberculosis. Emerg Infect Dis 2016; 22. doi: 10.3201/ eid2203.151430.
11. Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016; 20: 177–186.
12. South African Department of Health. Introduction of new drugs and drug regimens for the management of drug-resistant tuberculosis in South Africa. Pretoria, South Africa: DoH, 2015.
13. Guglielmetti L, Hewison C, Avaliani Z, et al. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. Int J Tuberc Lung Dis 2017; 21: 167–174.
14. World Health Organization. Ethics guidance for the implementation of the End TB Strategy. WHO/HTM/TB/ 2017.07. Geneva, Switzerland: WHO, 2017. http://www.who.int/tb/publications/2017/ethics-guidance/en/. Accessed July 2017.
15. World Health Organization. Implementing the End TB Strategy: the essentials. Geneva, Switzerland: WHO, 2015. WHO/HTM/ TB/2015.31. http://www.who.int/tb/publications/2015/end_tb_essential.pdf. Accessed July 2017.
16. Zumla A I, Gillespie S H, Hoelscher M. New anti-tuberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014; 14: 327–340.
17. Schatz A, Bugle E, Waksman S A. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. 1944. Clin Orthop Relat Res 2005; 437: 3–6.
18. Sims E. A case of tuberculous meningitis treated with streptomycin without success. Med J Aust 1947; 2: 12.
19. Fox W, Sutherland I, Daniels M. A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis. Q J Med 1954; 23: 347–366.
20. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLOS Med 2012; 9: e1001300.
21. Chan E, Strand M, Iseman M. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB. Clin Infect Dis 2009: 48; e50–52.
22. Kim D H, Kim H J, Park S K, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 113–119.
23. Migliori G B, Lange C, Centis R, et al. TBNET Study Group. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155–1159.
24. Falzon D, Gandhi N, Migliori G B, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156–168.
25. Althomsons S P, Cegielski J P. Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough. Int J Tuberc Lung Dis 2012; 16: 1331–1334.
26. Bastos M L, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first-and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364–1374.
27. Medical Research Council Investigation. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769–782.
28. Donald P, Sirgel F, Venter A, et al. The early bactericidal activity of streptomycin. Int J Tuberc Lung Dis 2002; 6: 693–698.
29. Donald P, Sirgel F, Venter A, et al. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2001; 5: 533–538.
30. Georghiou S B, Seifert M, Catanzaro D G, Garfein R S, Rodwell T C. Increased tuberculosis patient mortality associated with Mycobacterium tuberculosis mutations conferring resistance to second-line anti-tuberculous drugs. J Clin Microbiol 2017; 55: 1928–1937.
31. Oliveira J F, Cipullo J P, Burdmann E A. Aminoglycoside nephrotoxicity. Rev Bras Cir Cardiovasc 2006; 21: 444–452.
32. Kilonzo K G, Jones E S W, Okpechi I G, et al. Disparities in dialysis allocation: An audit from the new South Africa. PLOS ONE 2016; 12: e0176041.
33. Prayle A, Watson A, Fortnum H, et al. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 2010; 65: 654–658.
34. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007; 13: 119–126.
35. Guthrie O W. Aminoglycoside induced ototoxicity. Toxicology 2008; 249: 91–96.
36. Olusanya B O, Neumann K J, Saunders J E. The global burden of disabling hearing impairment: a call to action. Bull World Health Organ 2014; 92: 367–373.
37. Naismith J T. Deafness with use of dihydrostreptomycin in tuberculous meningitis. Br Med J 1952; 1: 796–798.
38. Degreef I. The ototoxicity of kanamycin: a theoretical and experimental study. Acta Otorhinolaryngolog Belg 1964; 18: 415–427.
39. Seddon J A, Godfrey-Faussett P, Jacobs K, et al. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012; 40: 1277–1286.
40. Kennedy B, O’Connor B, Korn B, Gibbons N, O’Connor T, Keane J. Multi-drug resistant tuberculosis: experiences of two tertiary referral centres. Ir Med J 2011; 104: 182–185.
41. Kuaban C, Noeske J, Rieder H L, Aït-Khaled N, Abena Foe J L, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517–524.
42. Piubello A, Harouna S H, Souleymane M B, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188–1194.
43. Baghaei P, Tabarsi P, Dorriz D, et al. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther 2011; 18: e29–e34.
44. Bloss E, Kuksa L, Holtz T H, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int J Tuberc Lung Dis 2010; 14: 275–281.
45. Burgos M, Gonzalez L C, Paz E A, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40: 968–975.
46. Chan E D, Laurel V, Strand M J, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103–1109.
47. Codecasa L R, Ferrara G, Ferrarese M, et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med 2006; 100: 1566–1572.
48. de Jager P, Van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622–627.
49. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798–1807.
50. Drobac P C, Mukherjee J S, Joseph J K, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117: 2022–2029.
51. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord 2007; 7: 5.
52. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648–655.
53. Geerligs W A, Van Altena R, De Lange W C M, Van Soolingen D, Van Der Werf T S. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758–764.
54. Ghafari N, Rogers C, Petersen L, Singh S A. The occurrence of auditory dysfunction in children with TB receiving ototoxic medication at a TB hospital in South Africa. Int J Pediatr Otorhinolaryngol 2015; 79: 1101–1105.
55. Isaakidis P, Cox H S, Varghese B, et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLOS ONE 2011; 6: e28066.
56. Jacob V, Robert L, Lebrun C, Laethem Y V, Sergysels R. Multidrug-resistant tuberculosis: a review of the 23 cases treated by the Saint-Pierre University Hospital (Brussels). Acta Clinica Belgica 2009; 64: 113–119.
57. Joseph P, Desai V B R, Mohan N S, et al. Outcome of standardized treatment for patients with MDR-TB from Tamilnadu, India. Indian J Med Res 2011; 133: 529–534.
58. Karagoz T, Yazicioglu Mocin O, Pazarli P, et al. The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment outcome. Tuberk Toraks 2009; 57: 383–392.
59. Keshavjee S, Gelmanova I Y, Farmer P E, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403–1409.
60. Kim H R, Hwang S S, Kim H J, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290–1295.
61. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318–326.
62. Malla P, Kanitz E E, Akhtar M, et al. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005–2006. PLOS ONE 2009; 4: e8313.
63. Masjedi M R, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002–2006. Int J Tuberc Lung Dis 2008; 12: 750–755.
64. Modongo C, Sobota R S, Kesenogile B, et al. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. BMC Infect Dis 2014. 14: 542.
65. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382–1384.
66. Palmero D J, Ambroggi M, Brea A, et al. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2004; 8: 778–784.
67. Peloquin C A, Berning S E, Nitta A T, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38: 1538–1544.
68. Sagwa E, Ruswa N, Musasa J P, Mantel-Teeuwisse A K. Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection. Drug Saf 2013; 36: 1087–1096.
69. Sturdy A, Goodman A, Jose R J, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011; 66: 1815–1820.
70. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170–174.
71. Telzak E E, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907–911.
72. Tupasi T E, Gupta R, Quelapio M I, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLOS Med 2006; 3: e352.
73. Uffredi M L, Truffot-Pernot C, Dautzenberg B, Renard M, Jarlier V, Robert J. An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents 2007; 29: 434–439.
74. Van Deun A, Maug A K, Salim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684–692.
75. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 744–751.
76. Modongo C, Pasipanodya J G, Zetola N M, Williams S M, Sirugo G, Gumbo T. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. Antimicrob Agents Chemother 2015; 59: 6337–6343.
77. Harris T, Bardien S, Schaaf H S, et al. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J 2012; 102: 363–366.
78. Brits J, Strauss S, Eloff Z, Becker P J, Swanepoel de W. Hearing profile of gold miners with and without tuberculosis. Occup Environ Med 2012; 69: 243–249.
79. American Speech-Language-Hearing Association. Guidelines for audiologic screening (guideline). Rockville, MD, USA: ASHA, 1997.
80. Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLOS ONE 2013; 8: e63057.
81. World Health Organization. Active tuberculosis drug-safety monitoring and management (aDSM): a framework for implementation. WHO/HTM/TB/2015.28. Geneva, Switzerland: WHO, 2015.
82. Sagwa E, Souverein P, Ribiero I, Leufkens H, Mantel-Teeuwisse A. Differences in VigiBasew reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment. Pharmacoepidemiol Drug Saf 2016; 26: 1–8.
83. Saliba J, Al-Reefi M, Carriere J, et al. Accuracy of mobile-based audiometry in the evaluation of hearing loss in quiet and noisy environments. Otolaryngol Head Neck Surg 2017; 156: 706–711.
84. Huth M E, Ricci A J, Cheng A G. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011; 2011: 937861.
85. Chen Y, Huang W-G, Zha D-J, et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res 2007; 226: 178–182.
86. Kranzer K, Elamin W F, Cox H, et al. A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. Thorax 2015; 70: 1070–1077.
87. Iijima K, Ara N, Abe Y, et al. Association of gastric acid and mucus secretion level with low-dose aspirin-induced gastropathy. Gastroenterol 2012; 47: 150–158.
88. Daftary A, Padayatchi N, O’Donnell M. Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Glob Public Health 2014; 9: 1107–1116.
89. Looi L, Ganten D, McGrath P, Gross M, Griffin G. Hearing loss: a global health issue. Lancet 2015; 385: 943–944.
90. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–1602.
91. Kouwenberg M, Rieffe C, Theunissen S C, de Rooij M. Peer victimization experienced by children and adolescents who are deaf or hard of hearing. PLOS ONE 2012; 7: e52174.
92. Tucci D, Merson M H, Wilson B S. A summary of the literature on global hearing impairment: current status and priorities for action. Otol Neurotol 2010; 31: 31–41.
93. Emmett S, Francis H. The socioeconomic impact of hearing loss on adults in the US. Otol Neurotol 2015; 36: 545–550.
94. Seddon J A, Thee S, Jacobs K, et al. Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect 2013; 66: 320–329.
95. Lessem E, Cox H, Daniels C, et al. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. Int J Infect Dis 2014; 32: 56–60.
96. Weiss P, Chen W, Cook V J, Johnston J C. Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infect Dis 2014; 14: 333.
97. Benbaba S, Isaakidis P, Das M, Jadhav S, Reid T, Furin J. Direct observation (DO) for drug-resistant tuberculosis: do we really DO? PLOS ONE 2015; 10: e0144936.
98. World Health Organization. The End TB Strategy. Geneva, Switzerland: WHO, 2017. http://www.who.int/tb/strategy/end-tb/en/. Accessed July 2017.
99. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim guidance. WHO/HTM/TB/2013.6. Geneva, Switzerland: WHO, 2013.
100. World Health Organization. A 2016 review of available evidence on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis. WHO/HTM/TB/2017.01. Geneva, Switzerland: WHO, 2017. http://www.who.int/tb/publications/2017/GDGreport_Bedaquiline/en/. Accessed July 2017.
101. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB2014.23. Geneva, Switzerland: WHO, 2014.
102. Hughes J. Better deaf than dead? Auckland Park, South Africa: Huffington Post, December 2016. http://www.huffingtonpost.co.za/doctors-without-borders/better-deaf-than-dead_a_21621566/ Accessed September 2017.
103. Lee M, Lee J, Carroll M W, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508–1518.
104. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015; 45: 161–170.
105. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447–454.
106. Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430–1442.
107. Diacon A H, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013; 57: 2199–2203.
108. Diacon A H, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949–954.
109. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLOS Med 2006; 3: e466.
110. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLOS ONE 2011; 6: e17556.
111. Gler M T, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151–2160.
112. Zumla A, Schito M, Maeurer M. Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers and vaccines. Lancet Infect Dis 2014; 14: 267–269.
113. Gugliemetti L, Jaspard M, Le Du D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1601799.
114. Pontali E, Sotgiu G, D’Ambrosio L, Centis R, Migliori G. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394–402.
115. Pai M, Furin J. Tuberculosis innovations mean little if they cannot save lives. eLife 2017; 6: e25956.
116. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979–985.
117. Ndjeka N. Incorporation of bedaquiline in the South African National TB Program. Poster presentation at the 2016 Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22–25 February 2016. Abstract no 754. http://www.croiconference.org/sessions/incorporation-bedaquiline-south-african-national-tb-programme Accessed July 2017.
118. Borisov S E, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017; 49. pii: 1700387.
119. Belard S, Heuvelings C C, Janssen S, Grobusch M P. Bedaquiline for the treatment of drug-resistant tuberculosis. Exp Rev Anti-infective Ther 2015; 13: 535–553.
120. Janssen Pharmaceuticals. TMC207 (bedaquiline) treatment of patients with MDR-TB (NDA 204–384). Briefing document to the Anti-Infective Drugs Advisory Committee Meeting, 28 November 2012. Beerse, Belgium: Janssen Pharmaceuticals, 2012.
121. Fox G, Menzies D. A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infect Dis Ther 2013; 2: 123–144.
122. Mitnick C D, Rusen I, Bain L J, Horsburgh C R. Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting. BMC Proc 2015; 9 (Suppl 8): S1.
123. Resist-TB Research Excellence to Stop TB Resistance. DR-TB Clinical Trials Progress Report. April 2017. http://www.resisttb.org/?page_id¼1602 Accessed July 2017.
124. Conradie F, Diacon A H, Everitt D, et al. The NIX-TB trial of pretomanid, bedaquiline and linezolid to treat XDR-TB. Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 13–16 February 2017. Abstract no 80LB. http://www.croiconference.org/sessions/nix-tb-trialpretomanid-bedaquiline-and-linezolid-treat-xdr-tb. Accessed July 2017.
125. Horsburgh C R, Rusen I D, Mitnick C D. Optimizing MDR-TB clinical trials: insights from the first global MDR-TB Clinical Trials Landscape Meeting. Int J Tuberc Lung Dis 2016; 20: 1–3.
126. Satta G, McHugh T D, Mountford J, Abubakar I, Lipman M. Managing pulmonary non-tuberculous mycobacterial infection: time for a patient-centered approach. Ann Am Thorac Soc 2014; 11: 117–121.
127. Isaakidis P, Rangan S, Pradhan A, Ladomirska J, Reid T, Kielmann K. ‘I cry every day’: experiences of patients co-infected with HIV and multidrug-resistant tuberculosis. Trop Med Int Health 2013; 18: 1128–1133.
128. Sullivan T, Amor Y. Global introduction of new multidrug-resistant tuberculosis drugs—balancing regulation with urgent patient needs. Emerg Infect Dis 2016; 22: e151228.
129. Kirby T. Landmark legal ruling sees Indian girl prescribed bedaquiline for XDR-TB. Lancet Respir Med 2017; 5: 249.
130. Kunkel A, Furin J, Cohen T. Population implications of the use of bedaquiline in persons with extensively drug-resistant tuberculosis: are fears of resistance justified? Lancet Infect Dis 2017 19 May 2017. http://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(17)30299-2.pdf. Accessed July 2017.
131. Citro B, Lyon E, Mankand M, et al. Developing a human rights-based approach to tuberculosis. Health Hum Rights. 2016; 18: 1–8.
132. Fitchett J R, MacPherson P, Corbett E. Implementing the End TB Strategy and the intersection with the sustainable development goals, 2016–2030. Trans R Soc Trop Med Hyg 2016; 110: 145–147.
133. Weld E D, Garcia-Prats A J, Furin J J, Bailey T C, Hesseling A C, Dooley K E. The time has come: sparing injectables in paediatric MDR-TB. Lancet Respir Med 2017 Mar 15. [Epub ahead of print].
134. Falzon D, Schünemann H, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: pii1602308.